Answers are grounded in this paper and cite their sources.
There are few therapeutic options to treat patients with sickle cell disease (SCD), a blood disorder caused by mutations in the β-globin gene that affects > 7M individuals worldwide. Combining human genetics and high-throughput proteomics can help identify new drug targets. Here, we present results from a proteogenomic analysis of the plasma proteome in SCD patients. We measured the levels of 5,411 plasma proteins and tested their associations with common genetic variation in 343 SCD patients. After conditional analyses, we identified 560 protein quantitative trait loci (pQTL), including 58 (10%) that are novel. Many of these pQTL are not specific to SCD patients and associate with clinically relevant traits in non-SCD African Americans from the Million Veteran Program (e.g., hemoglobin concentration, triglycerides). The effect sizes of the pQTL are largely concordant between SCD and non-SCD individuals, although we found examples (e.g., APOL1, haptoglobin) with evidence of heterogeneity that suggests an interaction between the plasma proteome and the SCD genotype. Finally, we combine pQTL and genome-wide association study results for fetal hemoglobin (HbF) in a Mendelian randomization analysis to prioritize four proteins that may increase HbF production (ENPP5, LBP, PTX3, ZP3). We have combined high-throughput DNA genotyping and plasma proteome profiling to confirm known and identify new genetic variants associated with protein level variation in SCD. Our results provide an opportunity to prioritize novel SCD drug targets that are informed by human genetics.
No takes yet. Share an insight, caveat, or question.
Groza et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: